To investigate the impact of XRA and Olap treatment on PCa cell fate decisions, we selected LNCaP, a metastatic, androgen-dependent, p53 wild-type PCa cell line that is characteristic of human prostatic adenocarcinoma [52,55]. The gene discussed is TP53; the disease is prostate adenocarcinoma.